Psoriasis plaques have a stubborn habit of returning to the exact same patches of skin, even after months or years of apparent remission. For the millions of people living with this chronic inflammatory condition, the pattern is maddening but not random. A growing body of research suggests that formerly affected skin stays “primed” because both skin cells (especially keratinocytes) and long-lived local immune cells retain a form of biological memory, which may make the same sites more likely to flare again even after symptoms fade.
The Immune Sentinels That Never Leave
When a psoriasis flare clears, the skin may look healthy, but the tissue tells a different story at the molecular level. Specific T cell populations, particularly Th22 and Tc17 subtypes, persist in the epidermis of clinically healed skin and can rapidly produce IL-22 and IL-17-related cytokines when stimulated. These are the same signaling molecules that drive the thickened, inflamed plaques characteristic of active disease. In effect, the immune system stations sentinels at former battle sites, ready to reignite inflammation at the first provocation.
These lingering cells belong to a broader category known as tissue-resident memory T cells, or Trm. Unlike most effector T cells, which die after an immune response resolves, Trm cells resist apoptosis and persist within previously affected tissues. In psoriasis, that persistence creates a localized disease memory. Other studies suggest that resolved psoriatic lesions can contain IL-17-producing T cell clones with tissue-residency markers, indicating these may be long-lived, locally anchored populations rather than generic immune cells passing through.
This immune memory helps explain why even highly effective systemic therapies rarely produce a clean slate. Once treatment is stopped, the same resident T cells can reawaken, responding to triggers such as skin injury or infection. Because they are already positioned in the epidermis and primed to respond, they can launch a rapid, localized inflammatory cascade without needing fresh recruitment from the bloodstream.
Keratinocytes Carry Their Own Scars
The memory problem extends beyond immune cells. Keratinocytes, the most abundant cells in the outer skin layer, also fail to fully reset after a flare resolves. Research published in the International Journal of Molecular Sciences found that keratinocytes from resolved psoriasis sites retain disease-residual transcriptomic and epigenomic profiles, including differences in DNA methylation and hydroxymethylation compared with skin that was never affected. These epigenetic marks function like molecular bookmarks, keeping certain inflammatory gene programs partially accessible even during remission.
This finding challenges a common assumption in dermatology: that clearing visible plaques means the underlying tissue has returned to normal. The epigenomic data suggest otherwise. Resolved skin occupies a middle state, neither fully diseased nor truly healthy, and that intermediate condition helps explain why the same locations are vulnerable to repeated flares. Earlier research has raised the possibility that structures distinct from T cells retain a form of “memory” in previously affected skin, and the keratinocyte data add evidence consistent with that idea.
In practical terms, this means that even when biologic drugs suppress systemic inflammation, the keratinocytes in previously involved skin remain unusually responsive. When exposed to cytokines such as IL-17 or IL-22, they can overreact, producing large quantities of chemokines and inflammatory mediators. Those signals then recruit and activate nearby immune cells, recreating the plaque microenvironment with remarkable fidelity.
Dendritic Cells as Relapse Triggers
If Trm cells and keratinocytes store the memory of past flares, a third cell type may help trigger recurrence. A study in Nature Communications identified a subset of dendritic cells marked by the surface protein CCR7 that express both IL-23A and IL-12B in psoriatic skin. These CCR7+ dendritic cells are tied to sustained IL-23 production and to reactivation of memory T17 programs, the very immune pathways that drive plaque formation.
The IL-23/IL-17 axis sits at the core of psoriasis pathology, a relationship established by extensive clinical and molecular work summarized in a recent disease overview of the condition. What the dendritic cell findings add is a specific cellular mechanism for how that axis gets switched back on in a localized way. Rather than a systemic immune surge, the data point to a neighborhood-level circuit: resident dendritic cells feed IL-23 to nearby memory T cells, which respond with IL-17, which in turn activates keratinocytes already epigenetically primed for inflammation. The result may be a flare that resembles its predecessor because many of the same cell types and signals are active in the same location.
Mapping the Inflammatory Neighborhood
Advances in single-cell and spatial sequencing have made it possible to visualize these cellular neighborhoods with new precision. A 2023 study in Nature Communications used both technologies to map the locations of cell types and active inflammatory pathways in psoriatic skin, showing how keratinocytes and fibroblasts amplify inflammatory responses in specific tissue compartments. The National Institutes of Health has highlighted how single-cell methods reveal diverse cell states in diseased versus healthy skin, identifying pathways that were previously invisible in bulk tissue analyses.
This spatial resolution matters because it shifts the scientific conversation from “what goes wrong in psoriasis” to “where exactly it goes wrong and why it keeps going wrong there.” The data show that inflammation is not evenly distributed across affected skin. Instead, tightly organized clusters of immune cells, keratinocytes, and stromal cells form self-reinforcing loops in defined zones. When treatment suppresses one element of the loop, the others can persist quietly and restart the cycle later.
Spatial maps also underscore that not every part of a plaque is equal. Some microdomains are dense with IL-23-producing dendritic cells and IL-17-producing T cells, while others are dominated by structural cells responding to those signals. This patchwork architecture helps clarify why partial responses to therapy are so common: drugs may effectively shut down one node of the network while leaving others relatively intact.
Why Current Treatments Fall Short
Biologic drugs targeting the IL-23/IL-17 axis have delivered significant improvements for many patients, often clearing large areas of skin. Yet the biological basis of recurrence remains an open problem. Longitudinal imaging and biopsy work show that even after plaques resolve, residual immune infiltrates and altered vasculature can persist in previously affected sites. These subtle abnormalities may not be visible to the naked eye, but they provide a scaffold on which full-blown inflammation can quickly rebuild.
The concept of disease memory suggests why stopping therapy frequently leads to relapse in the same locations. Systemic drugs can lower circulating cytokine levels and reduce the overall inflammatory burden, but they do not erase tissue-resident T cells, normalize keratinocyte epigenomes, or fully remodel the microvasculature. As a result, the threshold for reactivation in old lesion sites remains lower than in never-affected skin.
Another limitation is that most current treatments are designed around blocking specific cytokines or receptors, not around dismantling spatially organized cell circuits. If CCR7+ dendritic cells, Trm cells, and primed keratinocytes form a local feedback loop, then inhibiting a single cytokine may only temporarily interrupt communication without eliminating the participants. Once drug levels fall, the loop can resume its previous behavior.
Toward Therapies That Rewrite Skin Memory
Understanding psoriasis as a disease of tissue memory points toward new therapeutic strategies. One approach is to directly target resident T cells, either by selectively depleting them or by reprogramming them toward less inflammatory phenotypes. Another is to design interventions that modify keratinocyte epigenetic marks, pushing resolved skin closer to a truly normal state and raising the threshold for reactivation.
Researchers are also exploring ways to interfere with the local dendritic cell–T cell–keratinocyte circuit. If CCR7+ dendritic cells are key initiators of relapse, then blocking their survival, migration, or IL-23 production in previously affected skin could reduce the risk of plaques returning to the same spots. Combining such localized strategies with systemic biologics might offer more durable remission than either approach alone.
For patients and clinicians, these mechanistic insights help reframe expectations. Rather than viewing recurrence as a simple failure of treatment, it can be understood as the predictable consequence of a skin compartment that remembers. Clearing the surface is only the first step; the deeper challenge is persuading the tissue to forget.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
